Compare SPXX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPXX | CYBN |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.8M | 298.9M |
| IPO Year | N/A | N/A |
| Metric | SPXX | CYBN |
|---|---|---|
| Price | $18.02 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $74.50 |
| AVG Volume (30 Days) | 51.3K | ★ 613.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.57 | $4.81 |
| 52 Week High | $16.05 | $10.73 |
| Indicator | SPXX | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 49.06 |
| Support Level | $17.87 | $5.61 |
| Resistance Level | $18.11 | $6.20 |
| Average True Range (ATR) | 0.20 | 0.32 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 97.30 | 64.38 |
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.